Skin + Cancer
Connection
MC1R variants don't just affect your skin tone -- they directly elevate polygenic melanoma risk through the same biological pathway. This report unifies what your Skin Genomics panel found with the cancer consequence it implies.
⚠ Research Use Only. Not FDA-cleared or approved. Not intended to diagnose, treat, cure, or prevent any disease. Always discuss findings with a licensed healthcare provider.
See a fully rendered example -- real RSIDs, peer-reviewed citations, and clinical action guidance -- before you commit.
RSIDs analyzed in this panel
Representative variants. Full report includes all associated loci with genotyped values, effect sizes, and clinical interpretation.
Supporting literature
Hayward et al. Human Molecular Genetics 2022 (MC1R causal SNPs · naevus count). Sturm et al. J Investigative Dermatology 2016 (R-allele haplotype). Law et al. Nature Communications 2015 (SCC GWAS · 7,404 cases · 292,076 controls). Orlow et al./MSK 2022 (MC1R utility -- 92% screening uptake improvement).
Why skin genomics and melanoma risk must be read together
Your Skin Genomics report flags UV sensitivity via MC1R. But it does not quantify the cancer consequence of those same variants. MC1R R alleles impair pheomelanin-to-eumelanin switching -- the tanning response that protects against UV-induced DNA damage. The same locus that makes your skin react to sun also elevates your melanoma risk. These two panels are designed to be read together.
What to do with this information
Annual full-body skin examination with dermoscopy. Daily SPF 50+ broad-spectrum UVA/UVB protection year-round. Photographic mole mapping as a baseline. The MSK clinical utility study (Orlow et al. 2022) showed MC1R risk feedback improved screening uptake in 92% of patients who received it -- one of the highest clinical utility scores for any consumer genetic test.
This report is for Research Use Only and is not FDA-cleared, FDA-approved, or CE-IVD certified. Polygenic risk scores and pharmacogenomic findings reflect statistical associations from published peer-reviewed GWAS studies. Results are not diagnostic and do not constitute medical advice. Always consult a licensed physician, genetic counselor, or pharmacist before acting on any finding. © 2026 AuraGen Wellness · auragenwellness.com
- ✓Full MC1R haplotype -- R151C (rs1805007), R160W (rs1805008), D294H, D84E alleles
- ✓Melanoma PRS -- MC1R, TYR, SLC45A2, CLPTM1L, IRF4, ASIP, TP53
- ✓Basal Cell Carcinoma (BCC) -- IRF4 rs12203592 independent pathway
- ✓Naevus count genetic burden -- dermoscopy surveillance protocol included
- ✓UV-to-melanin conversion pathway -- the biological bridge explained
- ✓Annual dermatology surveillance protocol with dermoscopy recommendations
⚠ Research Use Only · Not FDA cleared